

## Auxellence announces engagement of Mr. Michael Lerner, principle owner of Lerner Finance Inc., for Corporate Financing and Corporate Update

VANCOUVER, BC, Monday, July 20, 2015 – Auxellence Health Corporation (CSE:AID, OTCQB: AXHLF, FRANKFURT: AUH, WKN: A14SUT) is pleased to announce that it has engaged Mr. Michael Lerner, principle of Lerner Finance Inc. of Toronto, Ontario, Canada, to assist with the issuer's corporate financing requirements.

Mr. Lerner has been working in the capital markets and institution equity sector for the past 18 years. As an institutional equity trader, at two of Canada's bank-owned dealers, he covered the largest US mutual funds and hedge fund client investing in Canadian equities, dealing with multi-million dollar transactions daily.

Mr. Lerner also ran a risk arbitrage hedge book for a Canadian bank where he traded many of the larger transactions in the Canadian public markets; including multiple offers on Falconbridge, Dofasco and Inco. In 2008, he began working for an independent broker dealer where he has led and participated in over 100 million dollars of financing for micro cap companies. He continues to be involved in the capital markets by consulting and assisting companies with their corporate financing requirements. In addition, he has taken roles in various public and private companies that he has worked with by serving as a director and/or officer.

The company would also like to provide a brief corporate update:

## **July 2015 Corporate Update**

- Auxellence has been in discussions with Intrinsic Venture Corp., since its termination of the original financing agreement, to determine a course of action to continue to work with Intrinsic.
- Auxellence previously announced that it had terminated the USA Distribution
  Agreement. The company, subject to final approval from the intellectual property
  holder and creator, has agreed to a new agreement under a non-exclusive basis subject
  to financing.
- Auxellence has completed the previously approved Plan of Arrangement from Supreme Court of BC. Details clarifying any remaining portions of the transaction will be issued shortly.
- Auxellence is in negotiations to extend terms within the General Service Agreement (GSA) with its primary medical device manufacturer and commercial operator as the company is in default.
- Auxellence had acquired the intellectual property underlying the company's interactive health care system (subject to certain terms and conditions). – The company continues to negotiate on the final terms as the company has not satisfied the funding terms for



final closing due to the initial financing agreement being uncompleted and terminated.

- The company is negotiating with an ECG based medical device firm for the Canadian rights of their product to be incorporated into the issuer's healthcare platform for nutraceutical and cosmeceutical skin health. The company believes it has come to a meeting of the minds for the transaction and will announce details as soon as they are finalized.
- The company continues to review opportunities in the medical monitoring, diagnostics and therapeutics fields, and expects to be able to bring significant value propositions to potential customers and shareholders. Management will provide further updates as they become available, and in the meantime continues toward closing the outstanding issues as itemized.

Contact:

Sydney Au, CEO Auxellence Health Corporation Email: ceo@auxellence.com

Phone: (604) 780-3311

## About Auxellence Health Corporation (CSE:AID)

Auxellence is a technology company engaged in the provision of medical monitoring, diagnostics, therapeutics and biomedical online services for common health problems. The company offers an extensive platform for physiologically interactive computing supporting therapeutic-diagnostic (theranostic) devices, expert systems, and recommender applications for personal health management. The initial focus is on weight management and skin conditions.

## Disclaimer for Forward-Looking Information

Statements in this press release regarding the Company which are not historical facts are "forwardlooking statements" that involve risks and uncertainties. Such information can generally be identified by the use of forwarding-looking wording such as "may", "will", "expect", "estimate", "anticipate", "intend", "believe" and "continue" or the negative thereof or similar variations. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated in such statements due to factors. The Company does not intend to update any changes to such statements, except as required by law. Although Management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES